Tag Archives: alny

Medicines Co., Alnylam Jump Ahead In Cholesterol Race

Biotechs The Medicines Co. (MDCO) and Alnylam Pharmaceuticals (ALNY) both got multiple price target increases Monday after they announced positive data on their anti-cholesterol drug candidate over the weekend. At the annual congress of the European Society of Cardiology, Medicines Co. and Alnylam presented results of their phase-one trial of ALN-PCSsc, which divided subjects with high LDL cholesterol (LDL-C) into various different dosage groups,

Alnylam Reports Data on Potential Alexion Rival Drug

Biotech Alnylam Pharmaceuticals (ALNY) reported positive data Friday on a rare-disease drug candidate and potential competitor to Alexion’s (ALXN) blockbuster Soliris. The market was underwhelmed, however, and Alnylam stock was down more than 3% in midday trading. Alnylam reported initial results from a phase 1/2 trial of ALN-CC5, a drug it’s developing with Sanofi’s (SNY) Genzyme division that targets complement component C5. Complements are

Alnylam Says Neurological Drug Passes Midstage Study

Alnylam Pharmaceuticals (ALNY) disclosed positive midstage testing results for its neurological drug patisiran, used to treat the potentially fatal disease transthyretin-mediated amyloidosis (TTM), a genetic disorder. The company said patisiran showed a mean 2.5-point reduction in a modified neuropathy impairment score after 12 months compared with an increase of 13 to 18 points in untreated patients. The study also stated that patisiran hit a